Project: Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer

Acronym PREVAlL (Reference Number: 11590)
Duration 01/03/2018 - 28/02/2021
Project Topic The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). A range of preclinical safety and efficacy experiments will be performed to nominate a clinical candidate from a recently discovered and highly potent series of ERRa inhibitors. The new candidate drug will be supported by strong safety and efficacy data packages and be ready for clinical trials within 18 months after completion of the project.
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 Lead Pharma Holding BV Coordinator Netherlands
2 3H Biomedical AB Partner Sweden
3 Axis Bioservices Ltd. Partner United Kingdom
4 Paraza Pharma Inc. Partner Canada